Drugs / Influenza vaccine GSK2186877A formulation 2
last change Dec 2010 re-read 2 minutes ago

Influenza vaccine GSK2186877A formulation 2

Vaccine

Developed for
influenza
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT01096056 Apr → Dec 2010 influenza GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Influenza vaccine GSK2186877A formulation 2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01096056
Modality Vaccine “influenza vaccine GSK2186877A formulation 2” NCT01096056
Route Intramuscular Intramuscular administration, 1 dose” NCT01096056